Table 1.

Patient demographics and baseline disease characteristics in patients with A) castration-resistant prostate cancer, B microsatellite-stable colorectal cancer, and (C) non–small-cell lung cancer

A. Castration-resistant prostate cancer
	Navarixin 30 mg + Pembrolizumab 200 mg	Navarixin 100 mg + Pembrolizumab 200 mg
	n = 20	n = 20
Age, median (range), y	74.5 (59–87)	71.0 (41–86)
<65, n (%)	4 (20)	7 (35)
≥65, n (%)	16 (80)	13 (65)
Sex, n (%)
Male	20 (100)	20 (100)
Female	0	0
ECOG PS, n (%)
0	4 (20)	8 (40)
1	16 (80)	12 (60)
No. of prior lines of therapy, n (%)
1	1 (5)	0
2	3 (15)	3 (15)
3	6 (30)	4 (20)
4	5 (25)	8 (40)
≥5	5 (25)	5 (25)
Missing	0	0
Prior PD-(L)1 treatment history, n (%)
Yes	1 (5)	0
No	19 (95)	20 (100)

B. Microsatellite-stable colorectal cancer
	Navarixin 30 mg + Pembrolizumab 200 mg	Navarixin 100 mg + Pembrolizumab 200 mg
	n = 19	n = 21
Age, median (range), y	55 (36–77)	59 (30–76)
<65, n (%)	15 (79)	17 (81)
≥65, n (%)	4 (21)	4 (19)
Sex, n (%)
Male	10 (53)	12 (57)
Female	9 (47)	9 (43)
ECOG PS, n (%)
0	3 (16)	12 (57)
1	16 (84)	9 (43)
No. of prior lines of therapy, n (%)
1	2 (11)	0
2	4 (21)	8 (38)
3	6 (32)	7 (33)
4	5 (26)	3 (14)
≥5	2 (11)	2 (10)
Missing	0	1 (5)
Prior PD-(L)1 treatment history, n (%)
Yes	0	0
No	19 (100)	21 (100)

C. Non–small-cell lung cancer
	Navarixin 30 mg + Pembrolizumab 200 mg	Navarixin 100 mg + Pembrolizumab 200 mg
	n = 12	n = 13
Age, median (range), y	63 (36–83)	71 (46–79)
<65, n (%)	6 (50)	4 (31)
≥65, n (%)	6 (50)	9 (69)
Sex, n (%)
Male	7 (58)	9 (69)
Female	5 (42)	4 (31)
ECOG PS, n (%)
0	4 (33)	5 (38)
1	8 (67)	8 (62)
No. of prior lines of therapy, n (%)a
1	3 (25)	4 (31)
2	4 (33)	5 (38)
3	4 (33)	0
4	1 (8)	3 (23)
≥5	0	0
Missing	0	0
Prior PD-(L)1 treatment history, n (%)
Yes	9 (75)	11 (85)
No	3 (25)	2 (15)

ECOG PS, Eastern Cooperative Oncology Group performance status; PD-L1, programmed cell death ligand 1

^aOne patient in the navarixin 100-mg arm received prior (neo)adjuvant therapy